{"protocolSection": {"identificationModule": {"nctId": "NCT00640562", "orgStudyIdInfo": {"id": "D1443L00031"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Quetiapine Extended Release Depression Symptoms", "officialTitle": "Comparison of Quetiapine Extended-Release (Seroquel XR\u2122) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study", "acronym": "ExAttitude"}, "statusModule": {"statusVerifiedDate": "2012-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-17", "studyFirstSubmitQcDate": "2008-03-17", "studyFirstPostDateStruct": {"date": "2008-03-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-29", "resultsFirstSubmitQcDate": "2012-05-17", "resultsFirstPostDateStruct": {"date": "2012-06-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-05-17", "lastUpdatePostDateStruct": {"date": "2012-06-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Aim of the study is to assess if the new compound Seroquel XR\u2122 is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.\n\nPLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA."}, "conditionsModule": {"conditions": ["Schizophrenia", "Depression"], "keywords": ["Schizophrenia", "Depression", "Quetiapine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 216, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Quetiapine Extended Release", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Quetiapine Extended Release"]}, {"label": "Risperidone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Risperidone"]}], "interventions": [{"type": "DRUG", "name": "Quetiapine Extended Release", "description": "Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day", "armGroupLabels": ["Quetiapine Extended Release"], "otherNames": ["Seroquel XR\u2122"]}, {"type": "DRUG", "name": "Risperidone", "description": "Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.", "armGroupLabels": ["Risperidone"], "otherNames": ["Risperdal"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.", "description": "The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.\n\nCDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.\n\nThe sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression.", "timeFrame": "12 week from baseline to last visit"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 12 of HAM-D Score", "description": "21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline.", "timeFrame": "12 weeks from baseline to last visit"}, {"measure": "Change From Baseline to Week 12 of PANSS Score", "description": "30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population.", "timeFrame": "12 weeks from baseline to last visit"}, {"measure": "- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score", "description": "The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits", "timeFrame": "12 weeks from baseline to last visit"}, {"measure": "CGI- Global Improvement Mean Score at Week 12", "description": "The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits", "timeFrame": "12week: descriptive statistic of CGI by visit and treatment"}, {"measure": "Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score", "description": "These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response", "timeFrame": "12 week from baseline to last visit"}, {"measure": "Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section", "description": "Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.\n\nThe SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40\n\nChange from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments.", "timeFrame": "12 weeks from baseline to last visit"}, {"measure": "Concomitant Use of Antidepressive Drugs From Baseline to Week 12", "description": "Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration", "timeFrame": "12 week from baseline to last visi"}, {"measure": "Change From Screening Visit to Week 12 of Prolactin Live", "description": "Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit", "timeFrame": "12 week from screening visit to last visit"}, {"measure": "Body Mass Index (BMI) at Week 12", "description": "Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment.", "timeFrame": "12 week"}, {"measure": "Concomitant Use of Antidepressive Drugs From Baseline to Week 12", "description": "Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration", "timeFrame": "Change of drug use from baseline to last visi"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of written informed consent\n* Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSM-IVTR\n* Baseline depressive symptoms, assessed by means of HAM-D (21-item) score \u226520, and HAM-D item 1 score \u22652\n\nExclusion Criteria:\n\n* Any DSM-IV Axis I disorder other than schizophrenia and schizoaffective disorder\n* Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period\n* Use of Clozapine within 28 days prior to enrollment or Clozapine non responders\n* Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug\n* An absolute neutrophil count (ANC) of \u22641.5 x 109 per liter\n* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Gino Montagnani, MD", "affiliation": "AstraZeneca", "role": "STUDY_CHAIR"}, {"name": "Mario diFiorino", "affiliation": "Ospedale Unico della Versilia (Lido di Camaiore, Lucca Italy)", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Fermo", "state": "AP", "country": "Italy", "geoPoint": {"lat": 43.16296, "lon": 13.72274}}, {"facility": "Research Site", "city": "Bergamo", "state": "BG", "country": "Italy", "geoPoint": {"lat": 45.69601, "lon": 9.66721}}, {"facility": "Research Site", "city": "Brindisi", "state": "BR", "country": "Italy", "geoPoint": {"lat": 40.63215, "lon": 17.93607}}, {"facility": "Research Site", "city": "Carbonia", "state": "CA", "country": "Italy", "geoPoint": {"lat": 39.16465, "lon": 8.5213}}, {"facility": "Research Site", "city": "Termoli", "state": "CB", "country": "Italy", "geoPoint": {"lat": 41.99994, "lon": 14.99389}}, {"facility": "Research Site", "city": "Aversa", "state": "CE", "country": "Italy", "geoPoint": {"lat": 40.97259, "lon": 14.20745}}, {"facility": "Research Site", "city": "Catania", "state": "CT", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Research Site", "city": "Nicosia", "state": "EN", "country": "Italy", "geoPoint": {"lat": 37.74747, "lon": 14.39218}}, {"facility": "Research Site", "city": "Lido Di Camaiore", "state": "LU", "country": "Italy", "geoPoint": {"lat": 43.90012, "lon": 10.2269}}, {"facility": "Research Site", "city": "Messina", "state": "ME", "country": "Italy", "geoPoint": {"lat": 38.19394, "lon": 15.55256}}, {"facility": "Research Site", "city": "Milazzo", "state": "ME", "country": "Italy", "geoPoint": {"lat": 38.22008, "lon": 15.24023}}, {"facility": "Research Site", "city": "Monza", "state": "MI", "country": "Italy", "geoPoint": {"lat": 45.58005, "lon": 9.27246}}, {"facility": "Research Site", "city": "Nocera Inferiore", "state": "SA", "country": "Italy", "geoPoint": {"lat": 40.7454, "lon": 14.64542}}, {"facility": "Research Site", "city": "Vallo Della Lucania", "state": "SA", "country": "Italy", "geoPoint": {"lat": 40.22786, "lon": 15.26635}}, {"facility": "Research Site", "city": "La Spezia", "state": "SP", "country": "Italy", "geoPoint": {"lat": 44.103, "lon": 9.82375}}, {"facility": "Research Site", "city": "Collegno", "state": "TO", "country": "Italy", "geoPoint": {"lat": 45.07873, "lon": 7.56735}}, {"facility": "Research Site", "city": "Frattaminore", "country": "Italy", "geoPoint": {"lat": 40.9558, "lon": 14.27201}}, {"facility": "Research Site", "city": "Lecco", "country": "Italy", "geoPoint": {"lat": 45.85589, "lon": 9.39704}}, {"facility": "Research Site", "city": "Palermo", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Research Site", "city": "Partinico", "country": "Italy", "geoPoint": {"lat": 38.04657, "lon": 13.11785}}, {"facility": "Research Site", "city": "Roma", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}]}, "referencesModule": {"references": [{"pmid": "25356632", "type": "DERIVED", "citation": "Kasper S, Montagnani G, Trespi G, Di Fiorino M. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. Int Clin Psychopharmacol. 2015 Jan;30(1):14-22. doi: 10.1097/YIC.0000000000000053."}, {"pmid": "24681810", "type": "DERIVED", "citation": "Di Fiorino M, Montagnani G, Trespi G, Kasper S. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. Int Clin Psychopharmacol. 2014 May;29(3):166-76. doi: 10.1097/YIC.0000000000000017."}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Adult male and female patients. with a diagnosis of schizophrenia or schizoaffective disorder (according to DSM-IVTR criteria). with depressive symptoms HAM-D baseline score \u2265 20. and HAM-D item 1 score \u22652.", "groups": [{"id": "FG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "FG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "109"}, {"groupId": "FG001", "numSubjects": "107"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "numSubjects": "81"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "26"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Known risperidone intolerance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Past use of Seroquel -stopped due to AE", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Low study drug dose", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Glycosylated Hemoglobin >8", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "BG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "103"}, {"groupId": "BG002", "value": "210"}]}], "measures": [{"title": "Age Continuous", "description": "Number of participants is lower than number in Participants Flow module. 6 participants, 2 in Seroquel XR and 4 in Risperidone, were not valid for safety population because they did not assume any study drug administration.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.46", "spread": "10.71"}, {"groupId": "BG001", "value": "42.08", "spread": "11.48"}, {"groupId": "BG002", "value": "42.27", "spread": "11.10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "91"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "63"}, {"groupId": "BG002", "value": "119"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.", "description": "The CDSS scale is used to assess the level of depression in schizophrenia and to estimate the severity of depressive symptoms.\n\nCDSS has 9 items rated on four-point scale: 0=absent; 1=mild; 2=moderate; 3=severe. Anchor point descriptions are provided to aid differentiation between each item score. The first eight items are rated on basis of patients' responses to questions; the 9 item is based on clinician's assessment.\n\nThe sum score is derived by adding the point score of all items (from 0 to 27 points); total score 4-5 is considered for minor depression and 6-7 score for major depression.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "12 week from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.31", "spread": "6.1", "lowerLimit": "6.10", "upperLimit": "NA"}, {"groupId": "OG001", "value": "5.53", "spread": "6.4", "lowerLimit": "6.40", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 of HAM-D Score", "description": "21-item scale for depression. Symptoms are rated finely (on a 5-point scale: absent; doubtful or trivial; mild: moderate severe) or coarsely (on a 3- point scale: absent; doubtful or mild; obvious, distinct, or severe).Total score range 0- 66, higher values represent worse outcome.Number of participants refers to valid for efficacy per protocol. Change:total score at week 12 minus total score at baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on scale", "timeFrame": "12 weeks from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-29.83", "spread": "10.13"}, {"groupId": "OG001", "value": "-23.02", "spread": "10.33"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 of PANSS Score", "description": "30-item scale where each symptom is rated on a severity ranging from 1-7. Symptoms are categorized into 7 items referring to positive, 7 items referring to negative and 16 general psychotic. Total score range 30- 210, higher values represent worse outcome. Number of participants analyzed refers to valid for efficacy per protocol population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on scale", "timeFrame": "12 weeks from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "102.26", "spread": "24.14"}, {"groupId": "OG001", "value": "100.51", "spread": "25.65"}]}]}]}, {"type": "SECONDARY", "title": "- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score", "description": "The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on scale", "timeFrame": "12 weeks from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.50", "spread": "1.33", "lowerLimit": "1.33", "upperLimit": "NA"}, {"groupId": "OG001", "value": "-1.04", "spread": "1.31", "lowerLimit": "1.31", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "CGI- Global Improvement Mean Score at Week 12", "description": "The CGI-S subset ranges from 1 to 7 such that a score of 1 indicates \"normal, not at all ill\", while a score of 7 indicates \"among the most extremely ill of patients\". The change from start of treatment (baseline V2) in the Severity of Illness will be calculated by subtracting the score at start of treatment (baseline V2) from the following visits", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "12week: descriptive statistic of CGI by visit and treatment", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "91", "spread": "4.47", "lowerLimit": "NA", "upperLimit": "NA"}, {"groupId": "OG001", "value": "88", "spread": "4.55", "lowerLimit": "NA", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score", "description": "These items are presented as self-report statements with which the patient agrees or disagrees. Each response is scored as +1 if correct or -1 if incorrect. The final score is the grand total of the positive and negative points. A positive score means a positive subjective response. A negative total score means a negative subjective response", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on scale", "timeFrame": "12 week from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86.38", "spread": "4.12", "lowerLimit": "4.12", "upperLimit": "NA"}, {"groupId": "OG001", "value": "76.64", "spread": "4.70", "lowerLimit": "4.70", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section", "description": "Extrapyramidal Side Effects (EPS) will be assessed using the Simpson-Angus Scale (SAS; Simpson GN et al 1970) . The CRF is source data for these assessments and day 0 is considered as baseline.\n\nThe SAS scale, containing 10 items, will be rated on a five-point scale where 0 is normal and 4 are severe symptoms. Min score =0, max score 40\n\nChange from start of treatment (day 0) will be calculated as the visit score minus the score at start of treatment for each of the neurological assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on scale", "timeFrame": "12 weeks from baseline to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.74", "spread": "5.29"}, {"groupId": "OG001", "value": "3.88", "spread": "5.24"}]}]}]}, {"type": "SECONDARY", "title": "Concomitant Use of Antidepressive Drugs From Baseline to Week 12", "description": "Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to safety population, that is to overall participants excluding 6 participants who did not assume any study drug administration", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "12 week from baseline to last visi", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Screening Visit to Week 12 of Prolactin Live", "description": "Plasma prolactin live was drawn prior to morning meal at the screening visit at the last visit", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "KG", "timeFrame": "12 week from screening visit to last visit", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "61.20", "spread": "29.77", "lowerLimit": "29.77", "upperLimit": "NA"}, {"groupId": "OG001", "value": "90.80", "spread": "55.78", "lowerLimit": "55.78", "upperLimit": "NA"}]}]}]}, {"type": "SECONDARY", "title": "Body Mass Index (BMI) at Week 12", "description": "Patient weight and height have been be collected in order to assess the Body Mass Index (BMI). The mean BMI values reported are assessed after 12 weeks of treatment.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kg/m^2", "timeFrame": "12 week", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.07", "spread": "6.65"}, {"groupId": "OG001", "value": "28.80", "spread": "5.31"}]}]}]}, {"type": "SECONDARY", "title": "Concomitant Use of Antidepressive Drugs From Baseline to Week 12", "description": "Number of concomitant users of antidepressive drugs during the study; the number of participants analyzed refers to ITT/safety population, that is to overall participants excluding the 6 participants who did not assume any study drug administration", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Change of drug use from baseline to last visi", "groups": [{"id": "OG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day"}, {"id": "OG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "17"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Seroquel XR", "description": "Seroquel XR dose uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day", "seriousNumAffected": 4, "seriousNumAtRisk": 109, "otherNumAffected": 28}, {"id": "EG001", "title": "Risperidone", "description": "Risperidone dose was uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.", "seriousNumAffected": 4, "seriousNumAtRisk": 107, "otherNumAffected": 21}], "seriousEvents": [{"term": "Disorientation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Psycotic Disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Extrapiramidal Syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Faint/Syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Acute Psycosis", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Acute Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Social Stay Hospitalisation", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Cardiocircolatory Arresti", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}], "otherEvents": [{"term": "Hyperprolactinemia", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 107}]}, {"term": "Dry Months", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 107}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 107}]}, {"term": "Weight Increse", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 107}]}, {"term": "Sedation", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 107}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 109}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 107}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Multicentre, randomized, open-label, flexible dose, parallel group, non inferiority"}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000003863", "term": "Depression"}, {"id": "D000003866", "term": "Depressive Disorder"}, {"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000001526", "term": "Behavioral Symptoms"}, {"id": "D000019964", "term": "Mood Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}, {"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}], "browseLeaves": [{"id": "M7061", "name": "Depressive Disorder", "asFound": "Depression", "relevance": "HIGH"}, {"id": "M7058", "name": "Depression", "asFound": "Depression", "relevance": "HIGH"}, {"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4818", "name": "Behavioral Symptoms", "relevance": "LOW"}, {"id": "M21835", "name": "Mood Disorders", "relevance": "LOW"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000018967", "term": "Risperidone"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000928", "term": "Antidepressive Agents"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}